0001784440 2026-01-01 2026-03-31 0001784440 2026-05-08 0001784440 2026-03-31 0001784440 2025-12-31 0001784440 2025-01-01 2025-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001784440 us-gaap:CommonStockMember 2024-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001784440 us-gaap:RetainedEarningsMember 2024-12-31 0001784440 2024-12-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001784440 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001784440 us-gaap:CommonStockMember 2025-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-03-31 0001784440 2025-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001784440 us-gaap:CommonStockMember 2025-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001784440 us-gaap:RetainedEarningsMember 2025-12-31 0001784440 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001784440 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001784440 us-gaap:CommonStockMember 2026-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001784440 us-gaap:RetainedEarningsMember 2026-03-31 0001784440 2025-01-01 2025-12-31 0001784440 2024-01-01 2024-12-31 0001784440 2025-12-01 2025-12-01 0001784440 2025-12-01 0001784440 us-gaap:RelatedPartyMember 2025-03-31 0001784440 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001784440 us-gaap:RelatedPartyMember 2026-03-31 0001784440 us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001784440 srt:MinimumMember 2025-09-10 0001784440 srt:MaximumMember 2025-09-10 0001784440 2025-09-10 2025-09-10 0001784440 srt:MaximumMember 2026-03-31 0001784440 srt:MinimumMember 2026-03-31 0001784440 us-gaap:PreferredStockMember 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001784440 us-gaap:SubsequentEventMember 2026-04-01 2026-05-08 shares iso4217:USD iso4217:USD shares notr:segment pure 10-Q true 2026-03-31 2026 false 333-234487 BIOSCIENCE HEALTH INNOVATIONS INC. NV 98-1498782 14857 South Concord Park Drive Bluffdale UT 84065 (801) 949-0791 None true Yes Yes Non-accelerated Filer true true true false 11416125

1145005

661925

78278

399257

874340

336348

95146

21341

137718

2069

2194838

1558658

82887

4400

48114

61236

135401

148523

2330239

1707181

6787

6274

22781

7957

79030

76749

136590

460402

645749

229851

140000

0.0001

250000000

11416125

10979058

1142

1098

1612234

1175211

71100

301007

1684490

1477330

2330239

1707181

750946

1227070

265350

330925

485596

896145

625809

433561

89694

35786

715503

469347

-229907

426798

-229907

426798

-0.02

0.01

-0.02

0.01

11376802

43916221

11376802

44336221

140000

10979058

1098

1175211

-341083

835240

426798

140000

10979058

1098

1175211

85715

1262038

140000

10979058

1098

1175211

301007

1477330

437067

437023

437067

-229907

140000

11416125

1142

1612234

71100

1684490

-229907

426798

-13122 0

-320979

-6836

537992

157377

-59841

25709

14824

14757

513

8189

73805

-3397

-552107

328309

30000

-30000

748120

589516

150000

522000

437067

1035187

67516

483080

365825

661925

662517

1145005

1028342

460402 0

Note 1 - Nature of Organization Nowtransit Inc. (the “Company,” “us,” “we,” “Nowtransit”) was incorporated in the State of Nevada on July 8, 2019, and changed its name to BioScience Health Innovations Inc on February 21, 2025. Through March 10, 2023 we had no operations and had not generated any material revenues since inception. Effective March 10, 2023, we closed on a Share Exchange Agreement with Best 365 Labs Inc. (“Best”), a Nevada corporation, wherein we acquired all of the shares of Best and Best became a wholly owned subsidiary of the Company. Best was incorporated on October 12, 2021 in the State of Nevada. Best sells clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels in the health and wellness market.

Note 2 - Liquidity The condensed consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, which assumes that the Company’s management will evaluate whether it will be able to meet its obligations and continue its operations in the normal course of business. The Company had net income of $642,090 and positive cash provided by operating activities of $172,178 for the year ended December 31, 2025. While the Company had a net loss of $229,907 during the three months ended March 31, 2026, they recorded accumulated earnings of $71,100, had net working capital of $1,549,089, and reported cash of $1,145,005 as of March 31, 2026, which management believes is sufficient to meet its obligations over the next year. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company determine it shall be unable to continue as a going concern.

642090

172178

-229907

71100

1549089

1145005

Note 3 - Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars and the Company has adopted a December 31 year end. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates. Segment Reporting The Company operates as a single operating and reportable segment as a retailer selling mental health and general wellness products. Our Chief Executive Officer, who serves as our Chief Operating Decision Maker (“CODM”), evaluates the Company’s financial performance and makes resource allocation decisions considering our one geographical area and on a consolidated basis. Accordingly, the CODM considers the revenue, operating expenses, and other income (expenses) of our single operating segment as reported on the statement of operations and considers our current and total assets as recorded on the balance sheet. There are no additional expense or asset information that are supplemental to those disclosed in these condensed consolidated financial statements that are regularly provided to the CODM. Cash and Cash Equivalents Cash and cash equivalents include cash on hand, cash in banks and any highly liquid investments with a maturity of three months or less to the extent the funds are not being held for investment purposes. As of March 31, 2026 and December 31, 2025, the Company had no cash equivalents. The Company maintains four accounts at Wells Fargo Bank. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. As of March 31, 2026 the Company has balances of $644,904 in excess of this limit. Accounts Receivable and Allowance for Doubtful Accounts The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of March 31, 2026 and December 31, 2025, the allowance for doubtful accounts was $0. Inventory The Company’s inventory is recognized in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of March 31, 2026 and December 31, 2025, the Company had $438,563 and $336,348 of finished goods on hand, respectively. And on March 31, 2026 and December 31, 2025, the Company had $435,777 and $0 of raw materials on hand respectively Income Taxes The provision for income taxes and deferred income taxes are determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.Revenue Recognition The Company’s revenue is recognized in accordance with Accounting Standards Codification 606 and the Company sells products in the immune health supplement market. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers that are end users of the Company’s products will generally remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. Customers that are resellers of the Company’s products are offered credit terms and generally pay within 30-60 days. As of March 31, 2026 and December 31, 2025 deferred revenue was $76,749 and $136,590, respectively. Shipping and handling costs that occur are paid by the customer and is not recorded as revenue. The Company has a policy to provide a refund on any product returned by the customer and refunds are recorded as a reduction in revenue. Refunds have been minimal to date. Advertising Costs Advertising costs are expensed as incurred. During the three months ended March 31, 2026 and 2025, the Company incurred advertising costs of $107,572 and $67,526, respectively. Research and Development The Company charges research and development costs to expense when incurred. During the three months ended March 31, 2026 and 2025, the Company incurred $49,722 and $37,540 in research and development expenses, respectively. Intangible Assets The Company accounts for its intangible assets in accordance with ASC 350. Costs incurred to renew or extend the term of intangible assets are expensed as incurred. As of the three months ended March 31, 2026, the Company incurred $82,887 to file certain patent applications that showcase the Company’s innovative approach to health and wellness solutions. The patent costs were capitalized and will be amortized on a straight-line basis over its estimated useful life once the patents are granted. During the year ended December 31, 2025 and 2024 no amortization expense was recorded as the patents were still pending. Amortization expense of $4,144 for each year ended December 31, 2027 and beyond. We have several patent applications pending in the U.S. and internationally for our innovative methylithioninium (methylene blue) and mitochondrial health compositions: Patent Pending Product Overview and Update U.S. Non-Provisional Patent Application No. 18/931,277 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024 International Patent Application No. PCT/US24/53487 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024 U.S. Non-Provisional Patent Application No. 18/931,346 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024 International Patent Application No. PCT/US24/53490 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024. Filed on 10/30/2024 U.S. Provisional Patent Application No. 63/712,895 for TREATMENTS USING METHYLTHIONINIUM SALT, SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND AND PHYSIOLOGICAL THERAPY, filed on 10/28/2024 U.S. Provisional Patent Application No. 63/754,434 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 2/5/2025 All provisional applications were filed with the U.S. Patent and Trademark Office by Thorpe North and Western. We believe these filings cover multiple potential patents and product opportunities. Leadership is actively exploring partnerships and strategic alliances to maximize value for stakeholders. All products and methods described remain patent pending as of the date of this filing.Impairment of Long-lived Assets The Company applies the provisions of ASC 360, where applicable, to all long-lived assets and periodically evaluates the carrying value of long-lived assets to be held and used for impairment. Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the three months ended March 31, 2026 and 2025, the Company recorded no impairment expense for their long-lived assets. Leases The Company follows the provisions of ASC 842, and records right-of-use (“ROU”) assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company’s leases is not readily determinable, the Company’s applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments. The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less. On December 1, 2025, we entered a 15-month rental arrangement for our office and inventory space, at which time we paid for the lease in full with a single payment of $65,610. Because there were no future lease payments to be made, we recorded an ROU asset at lease commencement for the value of the prepayment of $65,610 and had no lease liability to record. Before December 1, 2025, the Company had a month-to-month rental agreement. The Company recorded rent expense of $13,122 and $4,305, during the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, the weighted average remaining lease term was 11 months. Net Income (Loss) per Common Share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. As of March 31, 2026 and 2025 there were dilutive securities of 420,000 for the conversion of Series A Convertible Preferred Stock. These potentially dilutive securities were not included in the calculation of diluted net loss per common share at March 31, 2026 because they were antidilutive, therefore as of March 31, 2026, basic and diluted weighted average common shares outstanding and net loss per common share are the same. Recent Accounting Pronouncements The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined that there have been no standards that had, or will have, a material impact on its consolidated financial statements with exception to the following: In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires incremental disclosures about specific expense categories, including but not limited to, purchases of inventory, employee compensation, depreciation, amortization and selling expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted and the amendments may be applied either prospectively or retrospectively. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. The amendments only impact disclosures and are not expected to have an impact on the Company’s financial condition and results of operations.

250000

644904

438563

336348

435777

76749

136590

107572

67526

49722

37540

Intangible AssetsThe Company accounts for its intangible assets in accordance with ASC 350. Costs incurred to renew or extend the term of intangible assets are expensed as incurred. As of the three months ended March 31, 2026, the Company incurred $82,887 to file certain patent applications that showcase the Company’s innovative approach to health and wellness solutions. The patent costs were capitalized and will be amortized on a straight-line basis over its estimated useful life once the patents are granted. During the year ended December 31, 2025 and 2024 no amortization expense was recorded as the patents were still pending. Amortization expense of $4,144 for each year ended December 31, 2027 and beyond.We have several patent applications pending in the U.S. and internationally for our innovative methylithioninium (methylene blue) and mitochondrial health compositions:Patent Pending Product Overview and UpdateU.S. Non-Provisional Patent Application No. 18/931,277 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024International Patent Application No. PCT/US24/53487 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024U.S. Non-Provisional Patent Application No. 18/931,346 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024International Patent Application No. PCT/US24/53490 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024. Filed on 10/30/2024U.S. Provisional Patent Application No. 63/712,895 for TREATMENTS USING METHYLTHIONINIUM SALT, SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND AND PHYSIOLOGICAL THERAPY, filed on 10/28/2024U.S. Provisional Patent Application No. 63/754,434 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 2/5/2025All provisional applications were filed with the U.S. Patent and Trademark Office by Thorpe North and Western.We believe these filings cover multiple potential patents and product opportunities. Leadership is actively exploring partnerships and strategic alliances to maximize value for stakeholders.All products and methods described remain patent pending as of the date of this filing.

82887

4144

65610

13122

4305

P11M

420000

Note 4 - Related Party Transactions During the three months ended March 31, 2025 the Company purchased $456,556 worth of inventory from Ageless Holdings, LLC (“Holdings”), entity owned and controlled by the Company’s members of management and board of directors. Additionally, the Company received $132,960 worth of advances from Holdings to pay for operating expenses and the Company paid back $522,000 of the advances. During the three months ended March 31, 2026 the Company purchased $745,060 worth of inventory from Holdings, received $3,059 worth of advances from Holdings to pay for operating expenses, and paid back $150,000 of the advances. Additionally, during the first quarter of 2026 the Board of Directors decided to finalize a settlement agreement with Holdings and entered into a promissory note on March 28, 2026 for $460,402, which was equal to the amount owed to them as of that date. The note carries an interest rate of 7% per annum, can be prepaid at any time without penalty, and matures on December 31, 2026.

456556

132960

522000

745060

3059

150000

460402

0.07

Note 5 - Equity Common Stock The Company has 250,000,000, $0.0001 par value shares of voting common stock authorized. During the three months ended March 31, 2026, the Company issued 437,067 shares in common stock for cash proceeds of $437,067. On September 10, 2025, the Company filed a change in the articles of incorporation and increased the voting common stock from 75,000,000 to 250,000,000. In addition, the Company completed a 1 for 4 reverse common stock split, decreasing the number of voting common stock outstanding from 43,916,221 to 10,979,058. All share numbers presented in these consolidated financial statements have been retroactively adjusted for the stock split. During the three months ended March 31, 2025, there were no issuances of common stock. As of March 31, 2026 and December 31, 2025, the Company had 11,416,125 and 10,979,058 shares of common stock issued and outstanding, respectively. Preferred Stock On October 19, 2021, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing up to 5,000,000 shares of Preferred Stock, par value $0.0001 per share, with such rights, preferences and limitations as may be set forth in resolutions adopted by the Board of Directors. On November 1, 2021, the Company filed a Certificate of Designation designating 1,000,000 shares of Preferred Stock as Series A Convertible Preferred Stock (the “Series A”). Each share of the Series A is convertible into three shares of the Company’s common stock at the holder’s election, subject to a 4.99% beneficial ownership limitation which may be increased to 9.99% upon 61 days’ notice. During the three months ended March 31, 2026 and 2025 there were no issuances of preferred stock. As of March 31, 2026 and December 31, 2025, the Company had 140,000 shares of Series A Convertible Preferred Stock outstanding.

250000000

0.0001

437067

75000000

250000000

Company completed a 1 for 4 reverse common stock split

43916221

10979058

11416125

10979058

5000000

0.0001

1000000

Each share of the Series A is convertible into three shares of the Company’s common stock at the holder’s election, subject to a 4.99% beneficial ownership limitation which may be increased to 9.99% upon 61 days’ notice

140000

Note 6 - Subsequent Events The Company has evaluated all events that occur after the balance sheet date through April 28, 2026, the date when the financial statements were available to be issued, to determine if they must be reported. Management of the Company determined that there are no material subsequent events to be disclosed other than those described below. Subsequent to March 31, 2025, the Company issued 300,639 shares in common stock for cash proceeds of $300,639.

300639

false false false false

0001784440 false Q1 --12-31